Adalimumab

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Juvenile Rheumatoid Arthritis

Conditions

Juvenile Rheumatoid Arthritis

Trial Timeline

May 1, 2008 → Sep 1, 2011

NCT ID

NCT00690573

About Adalimumab

Adalimumab is a phase 3 stage product being developed by Eisai for Juvenile Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00690573. Target conditions include Juvenile Rheumatoid Arthritis.

What happened to similar drugs?

0 of 20 similar drugs in Juvenile Rheumatoid Arthritis were approved

Approved (0) Terminated (2) Active (18)

🔄PLX-200 + PlaceboPolaryx TherapeuticsPhase 3

🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3

🔄MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3

🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3

🔄AbataceptOno PharmaceuticalPhase 3

🔄Ixekizumab + AdalimumabEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01243671	Phase 3	Completed	Oct 1, 2010	Jun 1, 2013	Intestinal Behçet's Disease
NCT00690573	Phase 3	Completed	May 1, 2008	Sep 1, 2011	Juvenile Rheumatoid Arthritis
NCT00667355	Phase 3	Completed	Feb 1, 2008	Jan 1, 2011	Ankylosing Spondylitis
NCT00445432	Phase 2/3	Completed	Mar 1, 2007	Nov 1, 2010	Crohn's Disease
NCT00603993	Phase 3	Completed	Mar 1, 2006	—	Rheumatoid Arthritis
NCT00235872	Phase 3	Completed	Aug 1, 2004	—	Rheumatoid Arthritis
NCT00235833	Phase 2	Completed	Jun 1, 2003	—	Rheumatoid Arthritis

Competing Products

20 competing products in Juvenile Rheumatoid Arthritis

See all competitors

Product	Company	Stage	Hype Score
PLX-200 + Placebo	Polaryx Therapeutics	Phase 3	37
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
Abatacept	Ono Pharmaceutical	Phase 3	40
Ixekizumab + Adalimumab	Eli Lilly	Phase 3	44
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib	Eli Lilly	Phase 3	47
Baricitinib + Tocilizumab	Eli Lilly	Phase 3	47
adalimumab + Methotrexate	AbbVie	Pre-clinical	26
Upadacitinib	AbbVie	Phase 1	33
Upadacitinib + Tocilizumab	AbbVie	Phase 3	47
Adalimumab + Risankizumab	AbbVie	Phase 3	47
Adalimumab	AbbVie	Phase 3	40
naproxen + esomeprazole	AstraZeneca	Phase 1	29
Alendronate (Fosamax)	Merck	Pre-clinical	26
canakinumab	Novartis	Phase 3	40
Secukinumab	Novartis	Phase 1	36
ACZ885 150 mg (Canakinumab)	Novartis	Phase 3	40